<DOC>
	<DOCNO>NCT00117143</DOCNO>
	<brief_summary>The purpose study assess safety , tolerability , utility AMG 531 unit dosing ( Âµg ) thrombocytopenic subject ITP .</brief_summary>
	<brief_title>Amgen Megakaryopoiesis Protein 2 ( AMG 531 ) Thrombocytopenic Subjects With Immune Thrombocytopenic Purpura ( ITP )</brief_title>
	<detailed_description />
	<mesh_term>Purpura , Thrombocytopenic</mesh_term>
	<mesh_term>Purpura</mesh_term>
	<mesh_term>Purpura , Thrombocytopenic , Idiopathic</mesh_term>
	<criteria>Greater equal 3 month history ITP , regardless splenectomy status , completion least 1 prior treatment ITP 2 3 pretreatment platelet count less 30 x 10^9/L ( currently ITP therapy ) less 50 x 10^9/L ( currently receive corticosteroid ITP therapy ) Ability give informed consent Known history arterial thrombosis , active malignancy , bone marrow stem cell disorder</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>May 2009</verification_date>
	<keyword>Immune Thrombocytopenic Purpura</keyword>
	<keyword>Idiopathic Thrombocytopenic Purpura</keyword>
	<keyword>ITP</keyword>
	<keyword>Thrombocytopenia</keyword>
</DOC>